Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**99mTc-blue-biotin-liposomes** is a preclinical liposomal radiopharmaceutical imaging agent developed for sentinel lymph node radiolocalization. The formulation contains biotin-coated liposomes that co-encapsulate patent blue dye and glutathione, with technetium-99m incorporated through an HMPAO-glutathione radiolabeling method. After local administration, separately administered avidin binds the biotin surface, causing liposome aggregation and retention in the first draining lymph node; the patent blue dye enables visual identification and the technetium-99m label enables scintigraphic localization. It has also been investigated in rodents for avidin-mediated targeting of liposomes to peritoneal, mediastinal, and diaphragmatic lymph nodes. ([jnm.snmjournals.org](https://jnm.snmjournals.org/content/42/3/446.full.txt))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 99mTc-blue-biotin-liposomes.